RPL17 and non-small cell lung carcinoma: Hellmann et al. observed that first-line treatment with nivolumab (anti-PD 1 antibodies) combined with ipilimumab (anti-CTLA4 antibodies) resulted in a longer overall survival than that observed with chemotherapy in individuals with NSCLC, independent of the PD-L1 expression levels [58].